Precigen, Inc. (PGEN) Price Prediction 2026–2050

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms include AdenoVerse, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

Precigen is developing programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device.

The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Precigen, Inc. (PGEN) is a healthcare company with a current price of $5.21, a market capitalization of $1.86B, and a rank of 2093. These figures place the stock within a broad market segment that combines moderate price levels with a sizable enterprise value.

Near-term, the 2026 forecast for PGEN shows a min of $3.10, an avg of $5.21, and a max of $7.53, with a neutral sentiment and an implied ROI of 0%. This suggests a largely flat outlook around the current price in the immediate horizon.

Over the longer horizon, the forecast traces a bullish trajectory, with the avg price rising through subsequent years to support substantial upside by 2050. The path moves from 2027 avg $7.06 to 2050 avg $89.33, with higher max values along the way, and increasingly strong bullish sentiment.

The multi-year forecast paints a strong bullish path for Precigen, with the 2026 avg price at $5.21 and 2026 min $3.10 and max $7.53. By 2027, the avg price is forecast at $7.06 with a max of $9.90 and a min of $5.39, accompanied by a 35.5% ROI and bullish sentiment. The trajectory continues higher through 2028 ($8.41 avg, $12.39 max; 61.4% ROI) and 2029 ($9.15 avg, $14.02 max; 75.6% ROI).

In 2030, the avg forecast is $10.66 with a max of $16.87 and a min of $7.31, delivering a 104.7% ROI and a bullish outlook. The path extends to 2031 ($13.67 avg, $22.24 max; 162.4% ROI) and 2032 ($18.88 avg, $31.50 max; 262.4% ROI), then to 2033 ($22.07 avg, $37.65 max; 323.6% ROI) and 2034 ($21.87 avg, $38.09 max; 319.8% ROI).

Further out, 2035 is seen at $25.27 avg ($44.84 max; 384.9% ROI). The forecast then projects substantial upside in the 2040s, with 2040 avg $47.89, min $25.74, max $91.94 and an 819.2% ROI, and by 2050 an avg of $89.33, min $40.20, max $191.89 with a 1614.6% ROI. These figures imply a persistent bullish trend over the long term despite inherent uncertainty.

Drivers and risks: these are estimates and not guarantees; actual outcomes will depend on a range of factors including clinical progress, regulatory decisions, and market conditions. The forecast depicts potential upside across a broad horizon while acknowledging the typical volatility of healthcare equities and early-stage biopharmaceutical programs.